BioSpace News Archive

Castor, a leading provider of clinical trial technology that automates the research process, today announced that it has raised $12 million in funding.

FDA Introduces New Recommendation for 2-Year Annualized Bleeding Rate (ABR) as Primary Endpoint for Ongoing Phase 3 Study 270-301 Company Committed to Working with FDA to Align on Next Steps to Obtain Approval [19-August-2020]

Tyme Technologies, Inc. (NASDAQ: TYME, an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs ™ ), announced the appointment of John Rothman Ph.D. as Executive Vice President, Product Development. “Dr. Rothman is an accomplished pharmaceutical executive with an excellent record of developing important therapeutics for multiple indications worldwide,” said Steve Hoffman, Chairman and

ERC Belgium, a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer, has announced promising interim results in the phase 2 clinical trial for ERC1671 under FDA IND 15430 at the University of California, Irvine Medical Center in Orange, California.

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection.

Sirolimus, also known by its USAN-assigned generic name rapamycin, has gained traction in the medical and healthcare industries for its outstanding antitumor and immunosuppressive activities.

Global scleroderma therapeutics market is experiencing a major growth in coming years. The growth of the market is majorly driven by rising off-label use of drugs approved for symptomatic indications, for instance rheumatoid arthritis.

Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, reported financial results for the fourth quarter and fiscal year 2020, ended June 30, 2020.

The Study of KEDRAB®(Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S.

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced it has completed patient enrollment in its Phase I study evaluating PLX-R18 as a treatment for incomplete hematopoietic recovery following hematopoietic cell transplantation, in the U.S. and in Israel.